QuidelOrtho Corp
QDEL26.990USD
+0.180+0.67%
Handelsschluss 10/31, 16:00（ET）Kurse um 15 Minuten verzögert
1.83BMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über QuidelOrtho Corp Unternehmen
QuidelOrtho Corporation is engaged in vitro diagnostics, developing and manufacturing intelligent solutions. The Company sells its products directly to end users through a direct sales force and through a network of distributors, for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, other point-of-care (POC) settings, blood banks and donor centers, as well as for individual, non-professional, over the counter (OTC) use. The Company provides diagnostic testing solutions under various brand names, including AdenoPlus, BIOVUE, FreshCells, InflammaDry, Lyra, MeterPro, MicroVue, Ortho, Ortho Clinical Diagnostics, Ortho Connect, Ortho Plus, Ortho Vision, QuickVue, Quidel, QuidelOrtho, QVue, Savanna, Sofia, Solana, Thyretain, Triage, Virena, Vitros among others. It provides support for its customers across more than 130 countries and territories.
QuidelOrtho Corp Informationen
BörsenkürzelQDEL
Name des UnternehmensQuidelOrtho Corp
IPO-datumFeb 01, 1991
CEOMr. Brian J. Blaser
Anzahl der mitarbeiter6600
WertpapierartOrdinary Share
GeschäftsjahresendeFeb 01
Addresse9975 Summers Ridge Road
StadtSAN DIEGO
BörseNASDAQ Global Select Consolidated
LandUnited States of America
Postleitzahl92121
Telefon18585521100
Websitehttps://www.quidelortho.com/
BörsenkürzelQDEL
IPO-datumFeb 01, 1991
CEOMr. Brian J. Blaser
Führungskräfte von QuidelOrtho Corp
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Kenneth F. Buechler, Ph.D.
Dr. Kenneth F. Buechler, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
104.41K
+9.68%
Dr. Matthew W. Strobeck, Ph.D.
Dr. Matthew W. Strobeck, Ph.D.
Independent Director
Independent Director
72.55K
+7.29%
Mr. Joseph M. Busky
Mr. Joseph M. Busky
Chief Financial Officer
Chief Financial Officer
33.58K
+75.18%
Ms. Michelle A. Hodges, J.D.
Ms. Michelle A. Hodges, J.D.
Senior Vice President, Corporate Secretary, Chief Legal Officer
Senior Vice President, Corporate Secretary, Chief Legal Officer
29.40K
+0.65%
Mr. Edward L. (Ed) Michael
Mr. Edward L. (Ed) Michael
Independent Director
Independent Director
21.35K
+35.98%
Ms. Ann D. Rhoads
Ms. Ann D. Rhoads
Independent Director
Independent Director
14.27K
+75.49%
Mr. Brian J. Blaser
Mr. Brian J. Blaser
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
11.45K
--
Mr. John R. Chiminski
Mr. John R. Chiminski
Independent Director
Independent Director
2.52K
--
Sergio Gadaleta
Sergio Gadaleta
Senior Vice President - Clinical and Regulatory Affairs
Senior Vice President - Clinical and Regulatory Affairs
--
--
Devon Burek
Devon Burek
Senior Vice President - Global Quality
Senior Vice President - Global Quality
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Kenneth F. Buechler, Ph.D.
Dr. Kenneth F. Buechler, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
104.41K
+9.68%
Dr. Matthew W. Strobeck, Ph.D.
Dr. Matthew W. Strobeck, Ph.D.
Independent Director
Independent Director
72.55K
+7.29%
Mr. Joseph M. Busky
Mr. Joseph M. Busky
Chief Financial Officer
Chief Financial Officer
33.58K
+75.18%
Ms. Michelle A. Hodges, J.D.
Ms. Michelle A. Hodges, J.D.
Senior Vice President, Corporate Secretary, Chief Legal Officer
Senior Vice President, Corporate Secretary, Chief Legal Officer
29.40K
+0.65%
Mr. Edward L. (Ed) Michael
Mr. Edward L. (Ed) Michael
Independent Director
Independent Director
21.35K
+35.98%
Ms. Ann D. Rhoads
Ms. Ann D. Rhoads
Independent Director
Independent Director
14.27K
+75.49%
Umsatzaufteilung
Währung: USDAktualisiert: Mon, Oct 6
Währung: USDAktualisiert: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Labs
369.70M
60.22%
Immunohematology
132.30M
21.55%
Point-of-Care
93.00M
15.15%
Donor Screening
13.30M
2.17%
Molecular Diagnostic Solutions
5.60M
0.91%
Nach RegionUSD
Name
Umsatz
Anteil
North America
310.70M
50.61%
Other
132.50M
21.58%
EMEA
87.30M
14.22%
China
83.40M
13.59%
Nach Geschäftsbereich
Nach Region
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Labs
369.70M
60.22%
Immunohematology
132.30M
21.55%
Point-of-Care
93.00M
15.15%
Donor Screening
13.30M
2.17%
Molecular Diagnostic Solutions
5.60M
0.91%
Aktionärsstatistik
Aktualisiert: Wed, Oct 8
Aktualisiert: Wed, Oct 8
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
T. Rowe Price Investment Management, Inc.
16.40%
BlackRock Institutional Trust Company, N.A.
13.67%
The Vanguard Group, Inc.
11.44%
Rubric Capital Management LP
6.83%
State Street Investment Management (US)
3.98%
Andere
47.69%
Aktionäre
Aktionäre
Anteil
T. Rowe Price Investment Management, Inc.
16.40%
BlackRock Institutional Trust Company, N.A.
13.67%
The Vanguard Group, Inc.
11.44%
Rubric Capital Management LP
6.83%
State Street Investment Management (US)
3.98%
Andere
47.69%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
64.70%
Investment Advisor/Hedge Fund
33.01%
Hedge Fund
14.79%
Research Firm
2.13%
Pension Fund
1.21%
Individual Investor
0.94%
Private Equity
0.69%
Bank and Trust
0.65%
Sovereign Wealth Fund
0.52%
Institutionelle Beteiligung
Aktualisiert: Wed, Oct 1
Aktualisiert: Wed, Oct 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q3
649
79.57M
117.19%
-21.66M
2025Q2
684
78.51M
115.63%
-21.42M
2025Q1
726
76.59M
113.26%
-21.60M
2024Q4
747
75.07M
111.30%
-13.02M
2024Q3
744
73.58M
109.44%
-4.02M
2024Q2
767
70.18M
104.79%
-7.57M
2024Q1
799
67.05M
100.24%
-5.28M
2023Q4
828
68.21M
102.09%
-2.95M
2023Q3
842
70.19M
105.17%
-4.01M
2023Q2
860
68.99M
103.61%
-6.94M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
T. Rowe Price Investment Management, Inc.
11.14M
16.4%
-310.96K
-2.72%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
9.28M
13.67%
+1.73M
+22.86%
Jun 30, 2025
The Vanguard Group, Inc.
7.77M
11.44%
+1.04M
+15.55%
Jun 30, 2025
Rubric Capital Management LP
4.64M
6.83%
-1.50M
-24.47%
Jun 30, 2025
State Street Investment Management (US)
2.70M
3.98%
+510.29K
+23.29%
Jun 30, 2025
Fidelity Management & Research Company LLC
2.56M
3.76%
+1.30M
+103.23%
Jun 30, 2025
Dimensional Fund Advisors, L.P.
2.51M
3.69%
+691.35K
+38.04%
Jun 30, 2025
D. E. Shaw & Co., L.P.
2.01M
2.96%
+663.57K
+49.41%
Jun 30, 2025
American Century Investment Management, Inc.
1.92M
2.82%
+327.00K
+20.58%
Jun 30, 2025
AQR Capital Management, LLC
1.82M
2.68%
-838.33K
-31.57%
Jun 30, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Mon, Oct 6
Aktualisiert: Mon, Oct 6
Name
Anteil
SPDR S&P Health Care Equipment ETF
1.67%
Invesco S&P SmallCap Health Care ETF
1.28%
First Trust Nasdaq Lux Digi Health Solutions ETF
0.64%
JPMorgan Fundamental Data Science Small Core ETF
0.37%
Ballast Small/Mid Cap ETF
0.33%
SPDR S&P 600 Small Cap Value ETF
0.27%
iShares S&P Small-Cap 600 Value ETF
0.27%
Avantis US Small Cap Value ETF
0.27%
iShares U.S. Medical Devices ETF
0.22%
Avantis US Small Cap Equity ETF
0.2%
Mehr Anzeigen
SPDR S&P Health Care Equipment ETF
Anteil1.67%
Invesco S&P SmallCap Health Care ETF
Anteil1.28%
First Trust Nasdaq Lux Digi Health Solutions ETF
Anteil0.64%
JPMorgan Fundamental Data Science Small Core ETF
Anteil0.37%
Ballast Small/Mid Cap ETF
Anteil0.33%
SPDR S&P 600 Small Cap Value ETF
Anteil0.27%
iShares S&P Small-Cap 600 Value ETF
Anteil0.27%
Avantis US Small Cap Value ETF
Anteil0.27%
iShares U.S. Medical Devices ETF
Anteil0.22%
Avantis US Small Cap Equity ETF
Anteil0.2%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
